Skip to main content
Top
Published in: Journal of Nephrology 5/2022

18-03-2022 | original Article

Early morning hemodynamic changes and left ventricular hypertrophy and mortality in hemodialysis patients

Authors: Francesca Mallamaci, Rocco Tripepi, Claudia Torino, Giovanni Tripepi, Pantelis Sarafidis, Carmine Zoccali

Published in: Journal of Nephrology | Issue 5/2022

Login to get access

Abstract

Introduction

An exaggeration of the early morning increase in BP, a phenomenon accompanied by a parallel rise in heart rate (HR), is a marker of high cardiovascular risk. The early morning changes in these parameters have not been investigated in the hemodialysis population.

Methods

In a pilot, single center study including a series of 58 patients we measured the pre-awakening BP and HR surges and the nocturnal dipping of the same parameters as well as other established indicators of autonomic function (weighted 24 h systolic BP and HR variability) and tested their relationship with the left ventricular mass index (LVMI) and with the risk of death over a median follow up of 40 months.

Results

The pre-awakening HR surge (r = − 0.46, P = 0.001) but not the corresponding BP surge (r = − 0.1, P = 0.98) was associated with LVMI and the risk of death [HR (1 unit): 0.89, 95% CI 0.83–0.96, P = 0.001]. The link between the pre-awakening HR surge with these outcome measures was robust and largely independent of established risk factors in the hemodialysis population, including the nocturnal dipping of BP. Weighted 24 h systolic BP and HR variability did not correlate with LVMI (all P > 0.11) nor with the risk of death (P > 0.11) and were also independent of the nocturnal dipping of systolic BP and HR.

Conclusion

This pilot study suggests that the low early morning changes in HR, likely reflecting enhanced sympathetic activity, entail a high risk for left ventricular hypertrophy (LVH) and mortality in the hemodialysis population.
Literature
7.
go back to reference Sarafidis PA, Persu A, Agarwal R et al (2017) Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidne. Nephrol Dial Transpl 32:620–640. https://doi.org/10.1093/ndt/gfw433CrossRef Sarafidis PA, Persu A, Agarwal R et al (2017) Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidne. Nephrol Dial Transpl 32:620–640. https://​doi.​org/​10.​1093/​ndt/​gfw433CrossRef
11.
go back to reference Zoccali C, Benedetto FA, Mallamaci F et al (2001) Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12 Zoccali C, Benedetto FA, Mallamaci F et al (2001) Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12
Metadata
Title
Early morning hemodynamic changes and left ventricular hypertrophy and mortality in hemodialysis patients
Authors
Francesca Mallamaci
Rocco Tripepi
Claudia Torino
Giovanni Tripepi
Pantelis Sarafidis
Carmine Zoccali
Publication date
18-03-2022
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 5/2022
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-022-01281-5

Other articles of this Issue 5/2022

Journal of Nephrology 5/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.